Should You Continue to Hold Insulet Stock in Your Portfolio?

Key Takeaways Insulet gains from strong Omnipod 5 adoption, driving solid U.S. and international revenue growth.PODD benefits from a large underpenetrated diabetes market and expanding insulin pump adoption globally.Macroeconomic uncertainty, supply risks and intense competition may pressure Insulet's growth.Insulet (PODD) is well-poised to grow in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery (“AID”) system for both Type 1 and Type 2 populations. The diabe ...